Healius Ltd
ASX:HLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Healius Ltd
ASX:HLS
|
AU |
|
Getty Realty Corp
F:GRL
|
US |
|
T
|
Tuticorin Alkali Chemicals and Fertilizers Ltd
BSE:506808
|
IN |
Healius Ltd
Healius Ltd. engages in the provision of healthcare technology solutions. The company is headquartered in Sydney, New South Wales and currently employs 11,000 full-time employees. The firm operates through three segments: Pathology, Imaging and Day Hospitals. Pathology segment provides pathology services. Imaging segment offers imaging and scanning services from imaging sites, hospitals and from within the consolidated entity's medical centers. Day Hospitals segment is an operator of day hospitals and hematology or oncology services and provides services and facilities to In-Vitro Fertilization (IVF) specialists. The firm also provides facilities and support services to general practitioners, radiologists and a range of other healthcare professionals, enabling them to care their patients in partnership with the Company's pathologists, nurses and other employees.
Healius Ltd. engages in the provision of healthcare technology solutions. The company is headquartered in Sydney, New South Wales and currently employs 11,000 full-time employees. The firm operates through three segments: Pathology, Imaging and Day Hospitals. Pathology segment provides pathology services. Imaging segment offers imaging and scanning services from imaging sites, hospitals and from within the consolidated entity's medical centers. Day Hospitals segment is an operator of day hospitals and hematology or oncology services and provides services and facilities to In-Vitro Fertilization (IVF) specialists. The firm also provides facilities and support services to general practitioners, radiologists and a range of other healthcare professionals, enabling them to care their patients in partnership with the Company's pathologists, nurses and other employees.
Revenue Growth: Healius delivered 3.8% revenue growth to $688.1 million in 1H FY26, despite flat Medicare volumes and lower-than-normal episode volumes.
Profitability Improvement: Underlying EBITDA rose 13.1% to $122.2 million and group EBIT swung to $7.9 million from a loss, supported by improved cost control and operating leverage.
Cost Savings: The company achieved $10.7 million in additional annualized support cost savings in 1H (on top of $7.3 million from FY25), with more savings expected in H2.
Labor Optimization: Labor costs as a percentage of revenue declined to 49.3% in Q2, with management aiming for further reductions and flat absolute labor costs year-on-year (excluding Fair Work impacts).
Digital Transformation Complete: Major digital initiatives are now embedded and future digital spend will be treated as business as usual from January 2026.
Guidance Reaffirmed: FY26 EBIT is expected to be in line with consensus (~$48 million), with earnings and margins weighted to the second half due to seasonality and timing of cost savings.
Agilex Outperformance: Agilex Biolabs revenue grew 16% with EBIT up 145.5% and margin expanding to 12.4%, reflecting a shift to higher-value services.
Fair Work Commission Impacts: An initial $1.8 million cost impact expected for collectors in Q4 FY26, with further details pending on the full annualized impact.
